Derivados Quimicos S.A.
This represents for INFA GROUP an additional step – following the acquisition of Mediolast/Sifavitor in September 2007 – in creating a cluster of European API players based on the diversification and complementarities of its different elements.

This acquisition also confirms the full commitment of Investitori Associati – the main shareholder of INFA Group and one of most important Italian private equity funds– in developing its strategic project in pharma-chemical business.

With respect to Labochim and Sifavitor – the existing manufacturing units of INFA Group – Derivados Quimicos is positioning itself as an entity with a unique portfolio of technologies, such as Cyanation, Chlorination, Chlorosulfonation, Hydrogenation, Grignard reaction, Methylation, Nitration, Short Path Distillation and many others.

By aggregating Derivados Quimicos, INFA Group will benefit from these technologies both for captive use and to strengthen its custom synthesis market, thus providing enhanced solutions to its clients.

The Group will rely on 3 FDA inspected plants, on a product range of more than 110 leading molecules, on an R&D team cooperating with 4 European Universities with the availability of 2 pilot plants, presently managing over 20 active new projects and a marketing and sales network with offices in 6 different countries.

INFA Group has recently approved its 2007 consolidated accounts with a turnover of 85 million Euro for 2007. The turnover, on a pro-forma basis, including Derivados Quimicos would be more than 135 million Euro.

Daniele Cardoso, CEO of the INFA Group, Jesus Canovas, and their management teams are eager to start this mutual venture that confirms the potential of combining the skills of entrepreneurial family companies with the financial support of a professional investor.